siParadigm
diagnostic informatics

Requisition Number:

Pick-up confirmation #: _____

☐ STAT/RUSH ☐ Call for results

☐ Need results by: ____ /____ /____

SOLID TUMOR REQUISITION FORM (INFORMATION IN RED BOXES IS MANDATORY)

PATIENT INFORMATION

Name LAST FIRST

DOB (mm/dd/yy) | Gender ☐ Male ☐ Female ☐ Non-Binary

Street

City State ZIP

MRN/Patient ID/SSN # Phone #

SPECIMEN INFORMATION

Collection Date | Collection Time

Collection (Holding) Facility

Specimen ID Tel. #

Specimen Site | Primary Tumor

☐ Fresh Tissue/Fluid ☐ Urine Container(s) # ( )

☐ Paraffin Block(s) # ( ) ☐ Unstained Slide(s) # ( )

☐ Formalin Container(s) # ( ) ☐ Other# ( ) Specify:

PHYSICIAN INFORMATION

Primary MD

Account information

BILLING INFORMATION

☐ Insurance ☐ Client ☐ Patient

DATE OF DISCHARGE

SPECIFY STATUS FOR HOSPITAL PATIENTS

☐ In-patient ☐ Out-patient ☐ Non-Hospital

Please attach an Advance Beneficiary Notice (ABN) for all Medicare patients **Available at www.siparadigm.com**

ICD-10 Code

CLINICAL INFORMATION

Attach clinical notes, pathology reports & copies of both sides of insurance card(s)

Cancer Type

☐ Bladder Cancer ☐ Colorectal Cancer ☐ Melanoma ☐ Thyroid Cancer

☐ Brain Cancer ☐ Endometrial Cancer ☐ Ovarian Cancer ☐ Upper Gastrointestinal Cancers

☐ Breast Cancer ☐ Lung Cancer ☐ Prostate Cancer ☐ Other :

Cancer Status

☐ Primary Tumor ☐ Recurrent/Relapsed Disease ☐ Metastatic ☐ Advanced Stage ☐ Refractory ☐ Chemotherapy/ Adjuvant Treatment

I certify that I am licensed to order the following medically necessary tests. I authorize the release of specimens from the collection (holding) facility.

Authorized Signature **Date**

Level of service requested ☐ Complete consult ☐ Perform marked tests only

TMB and HRD testing for PARPi treatment are only available with the comprehensive 500 gene panel. Molecular testing cannot be performed on decalcified tissues.

☐ siPortfolio, Multi-Omics ($$$$) — TAT: 7-10 days

Includes:
- NGS (+500 genes, TMB, MSI)
- HRD for PARPi therapy
- IHC as clinically pertinent
- FISH as clinically pertinent

- **FFPE**
- **Blood (Lavender tube for HRD germline analysis)**

☐ Comprehensive NGS ($$$) — TAT: 7-10 days

Includes:
- NGS (+500 genes, TMB, MSI)
- HRD for PARPi therapy

- **FFPE, and**
- **Blood (Lavender tube for HRD germline analysis)**

☐ NGS 500 ($$) — TAT: 7-10 days

Includes:
- +500 genes-NGS Panel

Does not include:
- TMB
- MSI
- HRD

- **FFPE**

☐ HRD for PARPi Therapy ($$) — TAT: 7-10 days

- 46-gene-NGS panel for PARPi therapy
- Germline & somatic analysis

- **FFPE, and**
- **Blood (Lavender tube for HRD germline analysis)**

☐ NGS 50 ($) — TAT: 3-7 days

- NYS Approved
- 50 genes-NGS-panel that focuses on the genes recommended in the guidelines **(including NTRKs)** and other clinically significant ones

- **FFPE**

INDIVIDUAL TESTS

IHC

☐ ALK
☐ BRAF
☐ Breast IHC biomarkers (ER, PgR, Her2/nu & Ki67)
☐ ER
☐ HER2/neu
☐ If equivocal, reflex to Her2 FISH
☐ Ki67
☐ MET
☐ MMR (MLH1, MSH2, MSH6 & PMS2)
☐ NTRK "pan-TRK"
☐ PD-L1 22C3, FDA (KEYTRUDA®)
☐ PD-L1 28-8, FDA (OPDIVO®)
☐ PD-L1 SP263, FDA (IMFINZI®)
☐ PD-L1 SP142, FDA (TECENTRIQ®)
☐ PgR
☐ RET
☐ ROS1
☐ TP53



FISH

☐ 1p/19q Deletion
☐ ALK
☐ HER2/neu
☐ If equivocal, reflex to IHC
☐ MET
☐ PTEN Deletions
☐ RET
☐ ROS1
☐ **UroVysion® (use special container)**

MOLECULAR

☐ Androgen Receptor (AR)
☐ BRAF (incl. V600)
☐ BRCA1&2 (FFPE and blood required) for PARP inhibitors efficacy
☐ c-ERBB2 (HER-2/neu)
☐ EGFR
☐ IDH1/IDH2
☐ KRAS (12,13,61,117 & 146)
☐ MGMT Promoter Methylation
☐ MSI by NGS (TAT 7-10 days)
☐ NRAS (exons 2,3 & 4)
☐ PTEN
☐ RB1
☐ TP53
☐ Other: _____

25 Riverside Drive, Suite #2, Pine Brook, NJ, 07058
www.siparadigm.com

Version # April 2021

COLLEGE of AMERICAN PATHOLOGISTS

Clinical Laboratory Improvements Amendments

Continental U.S. Tel: 201.599.9044 Fax: 201.599.9066
PR/International Tel: 888.782.5430 Fax: 866.369.4114

siParadigm
diagnostic informatics

500 GENE TABLE

Hotspot Genes (n=57)

ACVR1, ATP1A1, BCR, BMP5, BTK, CACNA1D, CD79B, CSF1R, CTNNB1, CUL1, CYSLTR2, DGCR8, DROSHA, E2F1, EPAS1, FGF7, FOXL2, FOXO1, GLI1, GNA11, GNAQ, HIF1A, HIST1H2BD, HIST1H3B, HRAS, IDH1, IL6ST, IRF4, IRS4, KLF4, KNSTRN, MAP2K2, MED12, MYOD1, NSD2, NT5C2, NTRK2, NUP93, PAX5, PIK3CD, PIK3CG, PTPRD, RGS7, RHOA, RPL10, SIX1, SIX2, SNCAIP, SOS1, SOX2, SRSF2, STAT5B, TAF1, TGFBR1, TRRAP, TSHR, WAS

CNV Gain Genes (n=19)

ABCB1, CTNND2, DDR1, EMSY, FGF19, FGF23, FGF3, FGF4, FGF9, FYN, GLI3, IGF1R, MCL1, MDM2, MYCL, RPS6KB1, RPTOR, YAP1, YES1

Copy Number Variation and Hotspot Genes (n=108)

ABL1, ABL2, AKT1, AKT2, AKT3, ALK, AR, ARAF, AURKA, AURKC, AXL, BCL2, BCL2L12, BCL6, BRAF, CARD11, CBL, CCND1, CCND2, CCND3, CCNE1, CDK4, CDK6, CHD4, DDR2, EGFR, EIF1AX, ERBB2, ERBB3, ERBB4, ESR1, EZH2, FAM135B, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FLT4, FOXA1, GATA2, GNAS, H3F3A, H3F3B, IDH2, IKBKB, IL7R, KDR, KIT, KLF5, KRAS, MAGOH, MAP2K1, MAPK1, MAX, MDM4, MECOM, MEF2B, MET, MITF, MPL, MTOR, MYC, MYCN, MYD88, NFE2L2, NRAS, NTRK1, NTRK3, PCBP1, PDGFRA, PDGFRB, PIK3C2B, PIK3CA, PIK3CB, PIK3R2, PIM1, PLCG1, PPP2R1A, PPP6C, PRKACA, PTPN11, PXDNL, RAC1, RAF1, RARA, RET, RHEB, RICTOR, RIT1, ROS1, SETBP1, SF3B1, SLCO1B3, SMC1A, SMO, SPOP, SRC, STAT3, STAT6, TERT, TOP1, TPMT, U2AF1, USP8, XPO1, ZNF217, ZNF429

CNV Loss and CDS (n=205)

ABRAXAS1*, ACVR1B, ACVR2A, ADAMTS12, ADAMTS2, AMER1, APC, ARHGAP35, ARID1A, ARID1B, ARID2, ARID5B, ASXL1, ASXL2, ATM*, ATR*, ATRX, AXIN1, AXIN2, B2M, BAP1, BARD1*, BCOR, BLM*, BMPR2, BRCA1*, BRCA2*, BRIP1*, CASP8, CBFB, CD274, CD276, CDC73, CDH1, CDH10, CDK12*, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CHEK1*, CHEK2*, CIC, CREBBP, CSMD3, CTCF, CTLA4, CUL3, CUL4A, CUL4B, CYLD, CYP2C9, DAXX, DDX3X, DICER1, DNMT3A, DOCK3, DPYD, DSC1, DSC3, ELF3, ENO1, EP300, EPCAM, EPHA2, ERAP1, ERCC2, ERCC4, ERRFI1, ETV6, FANCA*, FANCC*, FANCD2*, FANCE*, FANCF*, FANCG*, FANCI*, FANCL*, FANCM*, FAT1, FBXW7, FUBP1, GATA3, GNA13, GPS2, HDAC2, HDAC9, HLA, A, HLA, B, HNF1A, INPP4B, JAK1, JAK2, JAK3, KDM5C, KDM6A, KEAP1, KMT2A, KMT2B, KMT2C, KMT2D, LARP4B, LATS1, LATS2, MAP2K4, MAP2K7, MAP3K1, MAP3K4, MAPK8, MEN1, MGA, MLH1, MLH3, MRE11*, MSH2, MSH3, MSH6, MTAP, MUTYH, NBN*, NCOR1, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, NOTCH4, PALB2*, PARP1*, PARP2, PARP3, PARP4, PBRM1, PDCD1, PDCD1LG2, PDIA3, PGD, PHF6, PIK3R1, PMS1, PMS2, POLD1*, POLE*, POT1, PPM1D, PPP2R2A*, PRDM1, PRDM9, PRKAR1A, PTCH1, PTEN*, PTPRT, RAD50*, RAD51*, RAD51B*, RAD51C*, RAD51D*, RAD52*, RAD54L*, RASA1, RASA2, RB1, RBM10, RECQL4, RNASEH2A*, RNASEH2B*, RNF43, RPA1*, RUNX1, SDHA, SDHB, SDHD, SETD2, SLX4, SMAD2, SMAD4, SMARCA4, SMARCB1, SOX9, SPEN, STAG2, STK11, SUFU, TAP1, TAP2, TBX3, TCF7L2, TET2, TGFBR2, TNFAIP3, TNFRSF14, TP53*, TP63, TPP2, TSC1, TSC2, USP9X, VHL, WT1, XRCC2*, XRCC3*, ZFHX3, ZMYM3, ZRSR2

CDS Only Genes (n=22)

CALR, CIITA, CYP2D6, ERAP2, ERCC5, FAS, ID3, KLHL13, MTUS2, PSMB10, PSMB8, PSMB9, RNASEH2C*, RPL22, RPL5, RUNX1T1, SDHC, SOCS1, STAT1, TMEM132D, UGT1A1, ZBTB20

TMB Only Genes (n=86)

A1CF, ACSM2B, ADAM18, ANO4, ARMC4, BRINP3, C6, C8A, C8B, CANX, CASR, CD163, CNTN6, CNTNAP4, CNTNAP5, COL11A1, DCAF4L2, DCDC1, GALNT17, GPR158, GRID2, HCN1, HLA, C, KCND2, KCNH7, KEL, KIR3DL1, KRTAP2, 1, KRTAP6, 2, LRRC7, MARCO, NLRC5, NOL4, NRXN1, NYAP2, OR10G8, OR2G6, OR2L13, OR2L2, OR2L8, OR2M3, OR2T3, OR2T33, OR2T4, OR2W3, OR4A15, OR4C15, OR4C6, OR4M1, OR4M2, OR5D18, OR5F1, OR5L1, OR5L2, OR6F1, OR8H2, OR8I2, OR8U1, ORC4, PAK5, PCDH17, PDE1A, PDE1C, PLXDC2, POM121L12, PPFIA2, RBP3, REG1A, REG1B, REG3A, REG3G, RPTN, RUNDC3B, SH3RF2, SLC15A2, SLC8A1, SYT10, SYT16, TAPBP, TPTE, TRHDE, TRIM48, TRIM51, ZIM3, ZNF479, ZNF536

Fusions (n=23)

ABL1, ALK, AKT3, AXL, BRAF, EGFR, ERBB2, ERG, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, PDGFRA, PPARG, RAF1, RET, ROS1

HRR GENES

HRR Genes (n=46)

ABRAXAS1, ATM, ATR, BARD1, BLM , BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM , MRE11, NBN, PALB2, PARP1, POLD1, POLE, PPP2R2A, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RNASEH2A, RNASEH2B, RNASEH2C, RPA1, TP53, XRCC2, XRCC3, BAP1, PARP2, PARP3, SLX4

50 GENE TABLE

DNA Hotspots (n=45)

AKT1, AKT2, AKT3, ALK, AR, ARAF, BRAF, CDK4, CDKN2A, CHEK2, CTNNB1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PIK3CA, PTEN, RAF1, RET1, ROS1, SMO, TP53

CNV (n=14)

ALK, AR, CD274, CDKN2A, EGFR, ERBB2, ERBB3, FGFR1, FGFR2, FGFR3, KRAS, MET, PIK3CA, PTEN

Inter-genetic Fusions (n=16)

ALK, BRAF, ESR1, FGFR1, FGFR2, FGFR3, MET, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, RET, ROS1, RSPO2, RSPO3

Intra-genetic Fusions (n=3)

AR, EGFR, MET

IHC

ALK, BRAF, ER, HER2/neu, Ki67, MET, MLH1, MSH2, MSH6, NTRK "pan-TRK", PD-L1 22C3, FDA (KEYTRUDA®), PD-L1 28-8, FDA (OPDIVO®), PD-L1 SP263, FDA (IMFINZI®), PD-L1 SP142, FDA (TECENTRIQ®), PgR, PMS2, TP53, ROS1, RET

FISH

1p/19q Deletion, ALK, HER2/neu, MET, PTEN Deletions, RET, ROS1, UroVysion®

For genes clinical relevance please visit www.siparadigm.com

CNV: Copy Number Variant | **CDS:** CoDing Sequence | **TMB:** Tumor Mutation Burden

25 Riverside Drive, Suite #2, Pine Brook, NJ, 07058
www.siparadigm.com
Version # April 2021

COLLEGE of AMERICAN PATHOLOGISTS

Clinical Laboratory Improvements Amendments

Continental U.S. Tel: 201.599.9044 Fax: 201.599.9066
PR/International Tel: 888.782.5430 Fax: 866.369.4114